Commentary: Can stem cell therapy reshape pharma's sales model?
This article was originally published in Scrip
Executive Summary
The pharmaceutical industry's foray into the new and rapidly evolving field of stem cell therapies will require an approach to commercialisation untested on traditional pharmaceutical medicines, say Andrew Millest, Su Webber and Mark Williams